Ranibizumab for age‐related macular degeneration: a meta‐analysis of dose effects and comparison with no anti‐VEGF treatment and bevacizumab

  title={Ranibizumab for age‐related macular degeneration: a meta‐analysis of dose effects and comparison with no anti‐VEGF treatment and bevacizumab},
  author={S. Jiang and C. Park and Jamie C. Barner},
  journal={Journal of Clinical Pharmacy and Therapeutics},
Ranibizumab is used monthly or as‐needed (PRN) for the treatment of age‐related macular degeneration. However, which treatment regimen is more effective remains unknown. The objectives of this study are to: (i) compare the efficacy of monthly versus as‐needed quarterly treatment; and (ii) compare the efficacy of ranibizumab 0·5 mg treatment with: (a) no anti‐vascular endothelial growth factor (VEGF); (b) ranibizumab 0·3 mg; and (c) bevacizumab. 

Anti‐vascular endothelial growth factors treatment of wet age‐related macular degeneration: from neurophysiology to cost‐effectiveness

Results seem to indicate that the application of VEP does not confer any additional benefits in the diagnosis or monitoring of wet AMD, and which anti-VEGF medication and injection protocol may be considered as most cost-effective.

Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration.

A bevacizumab step therapy protocol in routine clinical practice is effective for long-term treatment of nAMD.

Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

Overall, the results indicate that an individualized treatment approach with anti-VEGF using visual acuity and OCT-guided re-treatment criteria may be appropriate for most patients with nAMD.

Anti-Vascular Endothelial Growth Factor Dosing and Expected Acuity Outcome at 1 Year.

There appears to be a predictable, mathematically defined relationship between dose frequency and visual acuity change at 1 year in NAMD.

The Finnish national guideline for diagnosis, treatment and follow‐up of patients with wet age‐related macular degeneration

This work aimed to set evidence‐based medical guidelines for diagnosis, treatment and follow‐up of patients with wAMD.

Antiangiogenic Agents and Photodynamic Therapy

This chapter covers the causative factors of ocular angiogenesis and the possible pharmacological intervention to inhibit these factors in order to improve the vision of the patients.

Monoclonal Antibodies: A Therapeutic Option for the Treatment of Ophthalmic Diseases of the Eye Posterior Segment

Monoclonal antibodies, proteins produced by different processes that selectively bind to metabolites associated with diseases, are used for reducing the adverse effects of traditional treatments and improving the application of the drug in the area.

A History of Anti-VEGF Inhibitors in the Ophthalmic Literature: A Bibliographic Review

Purpose: This work aimed to analyze the 100 most-cited articles on antivascular endothelial growth factor (anti-VEGF) inhibitors. Methods: A literature search for anti-VEGF inhibitors using the Web

Detection of Pro- and Antiangiogenic Factors in the Human Sclera

Balancing anti- and proangiogenic factors actively regulates human scleral avascularity, inhibits endothelial cell growth in vitro, and thus may help maintaining the vascular privilege of the inner eye.



Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizuab administered monthly, although the comparison between bevacizumAB as needed and monthly bevicizumabs was inconclusive.

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

Ranibizumab and bevacizumAB are equally safe and efficacious in treating CNVM due to AMD.

Ranibizumab in neovascular age-related macular degeneration

There is growing evidence that intravitreal administration of ranibizumab and bevacIZumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

Evidence-based guidelines will help to optimise treatment outcomes with ranibizumab in neovascular AMD and continuous careful monitoring with flexible retreatment may help avoid vision loss recurring.